Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
Authors
Keywords
-
Journal
Cancer Cell International
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-07
DOI
10.1186/s12935-021-02072-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
- (2021) Issei Sumiyoshi et al. Journal of Translational Medicine
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutrophil dynamics in the tumor microenvironment
- (2021) Amanda J. McFarlane et al. JOURNAL OF CLINICAL INVESTIGATION
- Advances in immunotherapy for pancreatic ductal adenocarcinoma
- (2021) Motoki Miyazawa et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Blood tests predict the therapeutic prognosis of anti‐PD‐1 in advanced biliary tract cancer
- (2021) Fei Du et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
- (2021) Julia Peña-Asensio et al. Cancers
- The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
- (2021) Francesca Ligorio et al. Cancers
- Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
- (2021) Xiaona Fan et al. Frontiers in Cell and Developmental Biology
- Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
- (2021) G. Fornarini et al. ESMO Open
- Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
- (2020) Alessandro Russo et al. ADVANCES IN THERAPY
- Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis
- (2020) Jiawen Zhao et al. Cancer Cell International
- Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
- (2020) Jing Huang et al. LANCET ONCOLOGY
- Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
- (2020) Sirish Dharmapuri et al. Cancer Medicine
- Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy
- (2020) Adi Kartolo et al. Immunotherapy
- Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase
- (2020) Qi Xiong et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Monocyte and T Cell Immune Phenotypic Profiles Associated With Age Advancement Differ Between People With HIV, Lifestyle-Comparable Controls and Blood Donors
- (2020) Davide De Francesco et al. Frontiers in Immunology
- Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody
- (2020) Mehmet Akce et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy
- (2019) Yalong Qi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis
- (2019) Yan Wang et al. Annals of Translational Medicine
- High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy
- (2019) Edmund K. Bartlett et al. CANCER
- Role of the complement system in the tumor microenvironment
- (2019) Ronghua Zhang et al. Cancer Cell International
- Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
- (2018) Aya Nakaya et al. International Journal of Clinical Oncology
- Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
- (2018) Alessandro Russo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
- (2018) Aly-Khan A. Lalani et al. Journal for ImmunoTherapy of Cancer
- Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
- (2018) Katsutoshi Sekine et al. LUNG CANCER
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Esophageal cancer: The latest on chemoprevention and state of the art therapies
- (2016) Gregoire F. Le Bras et al. PHARMACOLOGICAL RESEARCH
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma
- (2015) Shinya Ohashi et al. GASTROENTEROLOGY
- Multifunctional receptor-targeting antibodies for cancer therapy
- (2015) Yanni Zhu et al. LANCET ONCOLOGY
- Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer
- (2014) X. Xie et al. DISEASES OF THE ESOPHAGUS
- Esophageal Carcinoma
- (2014) Anil K. Rustgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
- (2013) Graeme J.K. Guthrie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
- (2013) Virginia Hernandez–Gea et al. GASTROENTEROLOGY
- Oesophageal carcinoma
- (2013) Arjun Pennathur et al. LANCET
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now